Disclosed is a pharmaceutical composition for oral administration comprising a therapeutically effective amount of 5-azacytidine, wherein the composition releases the 5-azacytidine substantially in the stomach following oral administration to a subject. The composition is useful in the treatment of a disease associated with abnormal cell proliferation such as myelodysplastic syndrome or acute myelogenous leukaemia.